-
Phone
+44 7384 789152 -
Email
mdominikfischer@gmail.com -
Location
Oxford, United Kingdom
About
Professor M. Dominik Fischer
Surgeon, scientist and adviser at the leading edge of retinal disease and ocular gene therapy.
Professor Fischer is a consultant ophthalmic surgeon at the Oxford Eye Hospital and full Professor of Ophthalmology at the University of Oxford. He holds further professorships at the University of Tübingen and the University of Lausanne, and practises as consultant vitreoretinal surgeon at The Retina Clinic London. His work sits where clinical medicine, translational science and industry meet – the vantage point that makes his advice valuable to the companies and institutions working in this space.
After an MD awarded summa cum laude for research carried out as a visiting scholar at the University of Pennsylvania, he completed specialty and subspecialty training in Tübingen under Ulrich Bartz-Schmidt and Eberhart Zrenner. He earned a second doctorate, a DPhil at Oxford, for developing a new form of retinal gene therapy with Robert MacLaren. That combination of surgical training and laboratory science runs through everything he does.
Recipient of more than 25 international awards, including the Leonhard Klein Award for the advancement of vitreoretinal surgery and the Senator Hermann Wacker Award for scientific contributions to retinal disease.
Leadership in the field
A track record built on genuine world firsts
Professor Fischer continues to lead clinical trials in Oxford and Tübingen and is chief investigator of the first global post-approval safety study for ocular gene therapy. His work includes a series of genuine world firsts:
2015
World-first gene therapy targeting cones
2017
First stable XLRP gene therapy product
The first genetically stable investigational product for XLRP gene therapy, held on a joint patent.
2018
First phase III choroideremia treatment
2019
World-first ocular gene therapy safety study
2020
First-in-human PDE6A gene therapy
Standing and recognition
As a recognised key opinion leader, he serves on the advisory boards of patient advocacy groups, academic institutions and biotech and pharmaceutical companies, and has acted as expert adviser to governmental regulators. He has given around 150 invited lectures across the world and published roughly 100 peer-reviewed articles, with more than 3,500 citations and a cumulative impact factor near 400. He is the recipient of more than 25 awards, among them the Leonhard Klein Award for the advancement of vitreoretinal surgery and the Senator Hermann Wacker Award for scientific contributions to retinal disease.
Why it matters
Judgement from every side of the table
Few people combine surgical practice, trial leadership, laboratory science and industry advisory experience in one place. That range is the point. It means Professor Fischer can read a programme the way a regulator will, a clinician will, an investor will and a patient will – often in the same conversation.
Explore
Newsletter
© 2026 Fischer Consulting Limited
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.